Monocentric Analysis of the Effectiveness and Financial Consequences of the Use of Lenograstim versus Filgrastim for Mobilization of Peripheral Blood Progenitor Cells in Patients with Lymphoma and Myeloma Receiving Chemotherapy and Autologous Stem Cell Transplantation.
Umberto RestelliDavide CroceErminio BonizzoniMario MarzanattiAngelo AndreiniMarco SorioCristina TecchioErika BarisonFabio BenedettiPublished in: Journal of blood medicine (2020)
In our experience, Lenograstim outperforms Filgrastim in terms of effectiveness and lower cost. This study shows a clinical superiority of Lenograstim over Filgrastim suggesting a potential cost savings favoring Lenograstim.